Stockscreener 앱 받기
1.24
12.68%
-0.18
시간 외 거래:
1.26
0.02
+1.61%
Xortx Therapeutics Inc 주식(XRTX)의 최신 뉴스
XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis - Kalkine
XRTX Stock Jumps As Gout Drug Program Accelerates - StocksToTrade
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Canadian testing is expected to speed data for XORTX (XRTX)'s planned U.S. gout drug application. - Stock Titan
Global gout cases are expected to rise 70% over 25 years. XORTX plans to apply to study a gout drug in Canada. - Stock Titan
Why XORTX Therapeutics Inc. (NASDAQ:XRTX) Is In Focus Now? - Kalkine Media
XRTX Stock Whipsaws As XORTX Ramps Gout Drug Manufacturing - StocksToTrade
XORTX (XRTX) Stock Analysis: -6.74% Down — Bearish Signals to Watch 2026-09-17Insider Selling Alerts - dars.gov.et
XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis - kalkine.ca
XORTX Therapeutics Shares Rise 16.11% After HoursXORTX Therapeutics (NASDAQ:XRTX) - Benzinga
Xortx Therapeutics Inc Announces the Launch of Production of Drug Material and Tablet Manufacturing - marketscreener.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
XORTX Starts Clinical and Commercial Manufacturing of XORLO for Gout Program - TipRanks
XORTX Therapeutics (XRTX) begins making new gout drug - Stock Titan
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™ - The Manila Times
XORTX Therapeutics Initiates GMP Manufacturing of XORLO™ to Advance Gout Treatment Clinical Trials - Kalkine Media
XORTX Therapeutics (XRTX) commits $2.5M to investor outreach after TSXV delist - Stock Titan
Price to sales forward of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView
Price to earnings forward of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView
EBITDA margin % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
Return on invested capital % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Financial Statements – HAM:ANU - TradingView
Diluted shares outstanding of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Re-Engages Investor Relations Program - markets.businessinsider.com
XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile - TipRanks
XORTX Re-Engages Investor Relations Program - The Manila Times
XORTX Re-Engages Investor Relations Program - GlobeNewswire
XORTX Re-Engages Investor Relations Program - Moomoo
XORTX Therapeutics, Inc. Cash Flow – HAM:ANU - TradingView
XORTX Therapeutics (NASDAQ: XRTX) Signs New $2.5M Investor Relations Deal with IR Agency - kalkinemedia.com
Basic earnings per share (basic EPS) of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Balance Sheet – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Earnings and Revenue – HAM:ANU - TradingView
Discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Statistics – HAM:ANU - TradingView
Net income before discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics stock gains as Nasdaq listing takes center stage - ad-hoc-news.de
XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History - Yahoo Finance
XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign - TipRanks
$2.5M, three months, 10 campaigns: XORTX (Nasdaq: XRTX) bets big on investor marketing after TSXV delist - Stock Titan
XORTX Therapeutics (XRTX) Advances 2.94% to $2.17 as Traders Eye Move Toward $2.28 ResistanceOverbought Signal Alerts - siam.in
XORTX Therapeutics (TSXV:XRTX) Gains 4.59% as Kidney-Disease Pipeline and Sharper Capital Focus Support Positive Momentum - kalkine.ca
XORTX Announces Termination and Postponement of Investor Relations Program - marketscreener.com
XORTX Therapeutics Inc. (XRTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
XORTX Therapeutics Inc. (XRTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
XORTX Therapeutics (XRTX) to leave TSXV, delays $2.5M IR campaign - Stock Titan
XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting - TipRanks
XORTX Gets US$2.5M Back as TSX Venture Exchange Delisting Awaits Approval - Stock Titan
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - Value Research
XORTX Therapeutics (TSXV:XRTX) Shares Jump 10.8% in a Volatile Session - kalkine.ca
4.22%
자본화:
|
볼륨(24시간):